Is MoonLake Immunotherapeutics profitable?

MoonLake Immunotherapeutics is not currently profitable: it reported a net loss of $257.1M over the trailing twelve months.

What is MoonLake Immunotherapeutics's earnings per share?

MoonLake Immunotherapeutics's diluted EPS over the trailing twelve months is $-3.87.

Where does MoonLake Immunotherapeutics's income statement data come from?

Every line is extracted from MoonLake Immunotherapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

MoonLake Immunotherapeutics MLTX Income Statement

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY QoQ

Simplified Detailed

	TTM Q1 '26	TTM Q4 '25	TTM Q3 '25	TTM Q2 '25	TTM Q1 '25
Research and development	$220.92M+62.2%	$202.86M+79.9%	$187.22M+133%	$162.32M+210%	$136.22M+264%
Other operating expenses	$267.37M+56.6%	$244.84M+71.1%	$229.2M+111%	$200.88M+156%	$170.76M+180%
Total operating expenses	$267.37M+56.6%	$244.84M+71.1%	$229.2M+111%	$200.88M+156%	$170.76M+180%
Income tax expense	$1.08M+196%	$611K+117%	$404K+41.8%	$381K+71.7%	$365K+139%
Net income	-$257.08M-77.0%	-$227.32M-91.1%	-$210.5M-161%	-$176.16M-221%	-$145.21M-257%
Basic earnings per share	-$3.87-68.3%	-$3.52-86.2%	-$3.32-161%	-$2.78-212%	-$2.30-215%
Weighted-average shares, diluted	262.4M+4.2%	254.4M+1.2%	252.8M+6.4%	252.3M+10.6%	251.9M+20.5%
Weighted-average shares, basic	262.4M+4.2%	254.4M+1.2%	252.8M+6.4%	252.3M+10.6%	251.9M+20.5%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent	-$259.16M-78.1%	-$231.73M-99.1%	-$213.07M-162%	-$178.92M-243%	-$145.53M-274%
Increase in accrued expenses and other liabilities	——	——	$13.66M—	$2.91M—	$6.42M—
Increase (Decrease) in Prepaid Expense	$9.81M—	-$561K—	$8.67M—	——	——
Cash Provided by (Used in) Financing Activity, Including Discontinued Operation	$103.52M+40.9%	$146M+185%	$73.75M-7.3%	$73.46M-7.5%	$73.46M-86.2%
Cash Provided by (Used in) Investing Activity, Including Discontinued Operation	——	——	$85.57M—	——	——
Cash Provided by (Used in) Operating Activity, Including Discontinued Operation	-$224.15M-60.4%	-$196.01M-68.1%	-$185.69M-131%	-$166.42M-158%	-$139.78M-187%
Other Comprehensive Income Defined Benefit Plans Net Unamortized Gain Loss Arising During Period Net Of Tax	$187K—	$641K—	——	——	——
Unrealized gains (losses) on available-for-sale securities	-$2.29M-808%	-$5.12M-291%	-$2.74M—	-$2.81M—	-$252K—
Other comprehensive income (loss)	-$2.42M-646%	-$4.8M-285%	-$2.6M—	-$2.8M—	-$325K—
Other Nonoperating Income	$18.48M-20.7%	$22.37M+1.1%	$21.16M-18.9%	$24.19M+18.7%	$23.31M+52.1%
EBITDA	-$264.29M-56.1%	-$242.22M-70.9%	-$226.97M-111%	-$199.04M-157%	-$169.32M-180%
EBIT	-$267.37M-56.6%	-$244.84M-71.1%	-$229.2M-111%	-$200.88M-156%	-$170.76M-180%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Is MoonLake Immunotherapeutics profitable?: MoonLake Immunotherapeutics is not currently profitable: it reported a net loss of $257.1M over the trailing twelve months.
What is MoonLake Immunotherapeutics's earnings per share?: MoonLake Immunotherapeutics's diluted EPS over the trailing twelve months is $-3.87.
Where does MoonLake Immunotherapeutics's income statement data come from?: Every line is extracted from MoonLake Immunotherapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.